Apellis Pharmaceuticals, Inc. (APLS)

Market Cap	3.02B
Revenue (ttm)	781.37M
Net Income (ttm)	-197.88M
Shares Out	125.52M
EPS (ttm)	-1.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,284,716
Open	24.80
Previous Close	25.15
Day's Range	23.82 - 25.17
52-Week Range	23.82 - 64.58
Beta	0.92
Analysts	Buy
Price Target	45.71 (+89.98%)
Earnings Date	Feb 28, 2025

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 9, 2017
• Employees: 710
• Stock Exchange: NASDAQ
• Ticker Symbol: APLS
• Website: https://www.apellis.com

Financial Performance

In 2024, Apellis Pharmaceuticals's revenue was $781.37 million, an increase of 97.02% compared to the previous year's $396.59 million. Losses were -$197.88 million, -62.57% less than in 2023.

Analyst Forecast

According to 18 analysts, the average rating for APLS stock is "Buy." The 12-month stock price forecast is $45.71, which is an increase of 89.98% from the latest price.

Price Target

$45.71

(89.98% upside)

Analyst Consensus: Buy